ArticleLiver cancer2023

Low Baseline CXCL9 Predicts Early Progressive Disease in Unresectable HCC with Atezolizumab Plus Bevacizumab Treatment.

Shunichi Hosoda et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.